On August 4, OrthoPediatrics Corp. (NASDAQ:KIDS) reported second-quarter results that pushed revenue past $70 million for the first time in company history. The pediatric orthopedics specialist posted $70.5 million in total revenue, up 15% from $61.1 million a year earlier, and used the momentum to raise its full-year outlook. For a company that has spent years building toward scale in a narrow surgical niche, this was the quarter the numbers finally caught up to the ambition.
A Growth Engine Finding Its Stride
The headline number came from Trauma and Deformity, where revenue jumped 26% year over year to $52.6 million on August 4, powered by cannulated screws, the PNP Femur system, PediPlates, the Pega systems, and the newly added 3P Hip line. International sales grew even faster than domestic sales, climbing 22% to $15.7 million compared to 14% domestic growth to $54.8 million, a sign that OrthoPediatrics is not just winning share at home but exporting its model abroad. Profitability moved in step with the top line.
Gross margin expanded to 74% from 72%, and adjusted EBITDA more than doubled to $6.8 million from $4.1 million, evidence that the extra revenue is dropping through rather than being absorbed by costs. Free cash flow usage fell 78% to $3.1 million from $13.9 million, and management pointed to an exclusive distribution deal with OSSIO for bio-integrative, metal-free fixation technology as another lever for future growth. On the strength of all this, OrthoPediatrics raised its 2026 revenue guidance to a range of $265 million to $269 million from $263 million to $267 million, now implying 12% to 14% growth for the year.
Cracks Beneath the Record Numbers
The record top line did not erase the bottom line problem. Net loss for the quarter was $7.2 million, essentially unchanged from the $7.1 million loss a year earlier, even as revenue grew 15%. Total operating expenses rose 3% to $56.4 million, with sales and marketing costs up 11% on higher commissions and general and administrative expenses up 8% on added personnel supporting clinic expansions and small acquisitions.
Scoliosis, once a steady contributor, went the other direction, falling 9% to $16.9 million as 7D Technology revenue declined and international stocking distributors bought fewer sets, only partly offset by growth in Response Fusion and the newly added Verteglide. The company also swung from $3.6 million in other income a year ago to $2.9 million in other expense this quarter, driven by higher interest expense and foreign exchange losses tied to a weaker Euro. Cash, equivalents, short-term investments and restricted cash fell to $47.9 million as of June 30, 2026, from $62.9 million at the end of 2025.
What the Market Is Weighing
Hedge fund ownership rose to 19 funds from 18 in the prior quarter, a modest but real uptick in institutional conviction. Short interest sits at 4.8% of float, high enough to reflect a genuine bear camp rather than mere hedging noise. That combination suggests that the market is still debating whether the profitability inflection is durable. Neither figure points to a one-sided view of the stock right now.
Where the Story Goes Next
OrthoPediatrics has proven it can grow revenue at double-digit rates while widening margins and cutting cash burn, but the net loss has not budged, and scoliosis has turned into a drag rather than a driver. For the growth case to keep building, Trauma and Deformity and international sales need to keep outrunning the softness in scoliosis and 7D Technology. For the skeptics, the swing to other expense and the shrinking cash balance are reminders that the path to the company’s stated 2026 cash flow breakeven target still has to be walked, not just guided toward.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center